Envoy Medical Advances Acclaim PMA with Second FDA Module, Targeting 2027 Completion
Envoy Medical disclosed the second PMA module submission for the Acclaim cochlear implant, advancing a four-module rolling process. With two modules down, the company expects the final module with clinical data by end-Q2 2027, keeping the pivotal trial and U.S. commercialization timeline intact. While the Breakthrough Device Designation adds regulatory optimism, continued feedback cycles and capital needs remain key risks.
View signal analysis